Spironolactone

Introduction Overview

Generic Name

spironolactone

Brand Name

Aldactone, CaroSpir

Dosage Form

oral tablet, oral suspension

Drug Class

Aldosterone receptor antagonists, Potassium-sparing diuretics

Pharmacokinetics

Absorption:
Spironolactone is well absorbed orally with bioavailability reported to be approximately 60-90%. Absorption occurs primarily in the gastrointestinal tract with peak plasma concentrations of spironolactone and its active metabolites reached within 2-4 hours post-administration. Food intake does not significantly affect the extent of absorption but may delay Tmax. The oral suspension form (CaroSpir) provides an alternate formulation that allows for easier administration, especially in pediatric or geriatric populations.

Distribution:
After absorption, spironolactone is extensively bound to plasma proteins (~90%), primarily albumin. It distributes into tissues with a volume of distribution estimated at approximately 0.7 L/kg. The drug and its metabolites exhibit moderate lipophilicity, facilitating distribution into various organs, including the kidney and adrenal glands. The high plasma protein binding reduces the drug's free fraction but allows a reservoir effect contributing to sustained pharmacological activity.

Metabolism:
Spironolactone undergoes extensive first-pass hepatic metabolism. It is rapidly and extensively metabolized into several active metabolites, chiefly canrenone, 7-alpha-thiomethylspironolactone, and 6-beta-hydroxy-7-alpha-thiomethylspironolactone. These metabolites contribute significantly to the drug's pharmacological effects, often prolonging its half-life beyond that of the parent compound. The hepatic metabolism involves enzymatic pathways including reduction, hydrolysis, and conjugation.

Elimination:
Elimination of spironolactone and its metabolites occurs primarily via renal and biliary excretion. The parent drug has a half-life of approximately 1.3 to 2 hours, but the active metabolites have longer half-lives, typically ranging from 10 to 35 hours, contributing to the prolonged duration of action. The renal clearance is influenced by kidney function; thus, dose adjustments may be necessary in renal impairment. Approximately 47-51% of the dose is excreted in urine and 35-45% via feces as metabolites.

Dosage Forms

Available Dosage Forms:
Spironolactone is available in oral tablet and oral suspension formulations. The oral tablets are typically available in strengths such as 25 mg, 50 mg, and 100 mg. The oral suspension, marketed as CaroSpir, provides a liquid formulation for patients requiring dose flexibility or who have difficulty swallowing tablets.

Dosages for Adults and Adolescents:
For edema related to congestive heart failure, cirrhosis with ascites, or nephrotic syndrome, the oral dosage ranges from 25 to 200 mg daily, administered in single or divided doses. For hypertension management, the initial adult dose typically ranges from 50 to 100 mg per day. In congestive heart failure patients, initial dosing usually starts at 25 mg once daily, potentially increased to 50 mg once daily depending on tolerance and clinical response. For primary hyperaldosteronism, diagnostic dosing involves 400 mg daily for short or long testing protocols, while maintenance doses typically range from 100 to 400 mg daily. Hypokalemia treatment uses 25 to 100 mg per day.

Specific Patient Populations:
Patients with renal or hepatic impairment require careful monitoring due to altered pharmacokinetics, specifically reduced clearance and elevated risk for hyperkalemia and toxicity. Dosage adjustments or avoidance may be warranted in patients with Addison's disease, hyperkalemia, or those unable to urinate. Pregnant or breastfeeding women should use spironolactone only if benefits outweigh risks, under physician guidance. The liquid suspension is favored for pediatric use or persons with swallowing difficulties to enable accurate dosing.

Additional Notes:
Dosing regimens often start low to assess tolerance and electrolyte status before titration. Concomitant use with other diuretics has dosing considerations where spironolactone may remain constant while another diuretic dose is adjusted. Regular monitoring of serum potassium, renal function, and electrolytes is critical throughout therapy.

Mechanism Of Action

Spironolactone acts primarily as a competitive antagonist of aldosterone at mineralocorticoid receptors in the distal convoluted tubules and collecting ducts of the nephron. By blocking aldosterone binding, spironolactone prevents the transcriptional activation of sodium-potassium exchange proteins that facilitate sodium reabsorption and potassium excretion. This inhibition leads to increased sodium and water excretion while conserving potassium, defining its potassium-sparing diuretic properties.

At the molecular level, spironolactone and its active metabolites bind to the cytoplasmic mineralocorticoid receptor, preventing aldosterone-induced conformational changes that promote the recruitment of co-activators and subsequent gene transcription. This disrupts the expression of epithelial sodium channels (ENaC) and Na+/K+-ATPase pumps that mediate sodium retention. Consequently, this action reduces plasma volume and blood pressure while protecting against hypokalemia.

Beyond its diuretic and antihypertensive effects, spironolactone demonstrates anti-androgenic activity by blocking androgen receptors and inhibiting enzymes involved in androgen biosynthesis such as 17α-hydroxylase and 17,20-lyase. This biological effect explains its utility in conditions like acne and hirsutism. Unlike selective aldosterone receptor antagonists like eplerenone, spironolactone exhibits broader receptor interactions, contributing both to its therapeutic benefits and side-effect profile.

Clinically, spironolactone's aldosterone antagonism attenuates cardiac remodeling and fibrosis seen in heart failure by disrupting mineralocorticoid-mediated pathways. It also modulates electrolyte balance in patients with primary aldosteronism or secondary hyperaldosteronism, providing vital control over volume and potassium homeostasis. Its mechanism has been extensively validated through molecular pharmacology and clinical trials demonstrating improved morbidity and mortality in conditions such as severe heart failure.

Pharmacological Actions

Competitive antagonist of aldosterone at mineralocorticoid receptors.
Potassium-sparing diuretic effect by inhibiting sodium reabsorption in renal distal tubules.
Increases sodium and water excretion while conserving potassium and hydrogen ions.
Anti-androgenic effects via androgen receptor antagonism and inhibition of androgen synthesis enzymes.
Reduction of aldosterone-mediated cardiac fibrosis and ventricular remodeling.
Modulation of electrolyte balance in hyperaldosteronism and cirrhosis-induced edema.
Used as a diagnostic agent in primary hyperaldosteronism by assessing potassium response.
Exerts mild antihypertensive effects through reduction of plasma volume and vascular resistance.
Synergistic use with other diuretics that act proximally in the renal tubule enhances natriuresis.
Decreases morbidity and mortality in severe congestive heart failure when added to standard therapy.

Therapeutic Or Clinical Uses

Treatment of edema associated with congestive heart failure.
Management of fluid retention in liver cirrhosis with ascites.
Edematous states related to nephrotic syndrome unresponsive to other treatments.
Hypertension management, particularly in resistant cases.
Adjunctive therapy to reduce mortality in severe heart failure (NYHA class III-IV).
Diagnosis and treatment of primary hyperaldosteronism.
Treatment and prophylaxis of hypokalemia, especially in patients on digitalis.
Management of patients intolerant or partially responsive to other diuretics.
Off-label use in dermatology for androgen-dependent conditions like acne and hirsutism.
Potential use in hormone-related conditions due to anti-androgenic effects.

Side Or Adverse Effects

Hyperkalemia, potentially life-threatening if not monitored.
Gynecomastia, breast tenderness, and breast swelling in males due to anti-androgen effects.
Menstrual irregularities and amenorrhea in women.
Dizziness and lightheadedness, especially related to orthostatic hypotension.
Gastrointestinal disturbances including nausea, vomiting, and diarrhea.
Electrolyte imbalances such as hyponatremia, hyperchloremic metabolic acidosis.
Dehydration and volume depletion with excessive diuresis.
Rash, urticaria, and other hypersensitivity reactions less commonly observed.
Loss of libido and erectile dysfunction in some male patients.
Ambulatory hypotension or worsening renal function in predisposed individuals.
Potential tumorigenic effects observed in animal studies; clinical relevance uncertain.
Fatigue and lethargy reported in chronic use.
Muscle cramps and weakness associated with electrolyte disturbances.
Rare cases of hepatitis or cholestatic jaundice documented.
Elevated blood urea nitrogen and serum creatinine in renal impairment.

Precautions

Use cautiously in patients with renal impairment or elevated serum creatinine.
Monitor serum potassium closely to prevent hyperkalemia, especially with concurrent potassium supplements.
Avoid use in patients with Addison's disease due to risk of adrenal insufficiency.
Discontinue or adjust dose prior to surgery or invasive procedures.
Use with caution in hepatic impairment; risk of hepatic encephalopathy due to electrolyte disturbances.
Avoid concomitant use with other potassium-sparing agents or potassium supplements unless closely monitored.
Use cautiously in patients with electrolyte imbalances, including hyponatremia or hypomagnesemia.
Avoid use in anuric patients or those unable to produce urine.
Monitor for signs of hormonal side effects in males and females (gynecomastia, menstrual changes).
Pregnancy use only if clearly needed; benefits should outweigh risks after physician assessment.
Exercise caution in breastfeeding women; assess risk-benefit ratio.
Avoid abrupt discontinuation to prevent rebound fluid retention or electrolyte imbalances.
Use caution when combined with NSAIDs due to potential for decreased diuretic efficacy and renal function impairment.
Adjust dose in elderly patients due to altered pharmacokinetics and increased susceptibility to adverse effects.
Regularly monitor blood pressure, renal function, and electrolytes throughout therapy.

Warnings

Avoid use in patients with hyperkalemia or predisposition to elevated potassium levels.
Contraindicated in patients with Addison's disease or severe renal failure with anuria.
Risk of tumorigenesis observed in animal studies, though significance in humans is unknown.
Can cause severe electrolyte imbalances; monitoring is mandatory during treatment.
Potential for severe hypersensitivity reactions including angioedema.
May cause dizziness or impaired ability to perform hazardous tasks; avoid driving until effects are known.
Use cautiously when combined with eplerenone; may exacerbate hyperkalemia.
Risk of gynecomastia and endocrine side effects with prolonged use.
Discontinue immediately if signs of allergic reaction or serious adverse effects occur.
Caution in patients with hepatic cirrhosis; worsening encephalopathy may occur.
Pregnancy Category C; use only if potential benefit justifies potential risk to fetus.
May interfere with diagnostic tests; inform healthcare providers of therapy.
Avoid concurrent use with potassium supplements or salt substitutes unless directed by physician.
Abrupt withdrawal may cause fluid retention and rebound hypertension.
Monitor for signs of dehydration or hypotension especially in elderly or volume-depleted patients.

Contraindication

Known hypersensitivity or allergy to spironolactone or any components of the formulation.
Addison's disease (primary adrenal insufficiency).
Hyperkalemia or elevated baseline serum potassium levels.
Anuria or severe renal impairment with inability to urinate.
Concomitant use with eplerenone due to additive risk of hyperkalemia.
Pregnancy unless no safer alternatives; risks must be carefully considered.
Use in patients with electrolyte imbalances that cannot be corrected prior to therapy.
Avoid use during breastfeeding unless benefits outweigh risks.

Drug Interactions

Concurrent use with potassium supplements or potassium-sparing diuretics increases risk of hyperkalemia.
NSAIDs (e.g., aspirin, ibuprofen, naproxen) may reduce diuretic efficacy and impair renal function.
Concurrent use with ACE inhibitors or angiotensin receptor blockers can potentiate hyperkalemia risk.
Coadministration with lithium may increase lithium toxicity due to reduced renal clearance.
Trimethoprim can increase serum potassium; additive hyperkalemia risk when used with spironolactone.
Colchicine plasma levels and toxicity may be affected by spironolactone.
Digoxin levels may be altered; monitoring for digoxin toxicity is advised.
Drugs causing dizziness (opioids, muscle relaxants, benzodiazepines) may worsen this effect when combined.
Drugs affecting electrolyte balance (e.g., corticosteroids, amphotericin B) may interact adversely.
Diuretics that increase potassium loss (e.g., loop diuretics, thiazides) may require dose adjustments.
Use with antiarrhythmic agents requires caution due to electrolyte and cardiac conduction effects.
Combination with drugs metabolized by hepatic enzymes may alter spironolactone metabolism.
Synergistic hypotensive effects with other antihypertensives necessitate blood pressure monitoring.
CYP3A4 inhibitors or inducers may affect spironolactone metabolism and plasma levels.
Herbal products affecting potassium (e.g., licorice, aloe) may antagonize or enhance effects.

Preparations Of The Drug

Spironolactone oral tablets available in 25 mg, 50 mg, and 100 mg strengths.
CaroSpir oral suspension formulation for pediatric and adult use requiring flexible dosing.
Standard packaging includes blister packs or bottles for tablets; calibrated bottles for suspension.
Formulations designed to be taken once or twice daily depending on indication and dose.
Extended-release formulations are not commonly available; immediate release is standard.
Available as generic and brand-name products to enhance accessibility and affordability.
Formulations compatible with concurrent use with other oral medications.
Storage at room temperature, away from heat, moisture, and light is recommended.
Suspension requires shaking prior to administration to ensure dose consistency.
Manufacturers provide detailed patient and caregiver medication guides with each preparation.
Preparation labels include comprehensive dosing instructions and warnings for safe use.
Prescribed preparations often tailored for specific indications and patient populations.
Reformulations under investigation include combined therapy tablets with other diuretics.
Packaging incorporates child-resistant caps to prevent accidental ingestion.
Parenteral formulations of spironolactone are not available; oral route is sole administration method.